Study Shows Cost-Saving Potential of CytoSorb Therapy in Cardiac Surgery

A health economic cost analysis of acute endocarditis patients treated with CytoSorb during
open heart surgery suggests significant saving opportunities.
The analysis is based on a 2017 published study of Prof. Dr. med. Karl Träger.

Munich, February 21, 2019 – CytoSorbents, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the outcomes of a recent analysis at the 48th Annual Meeting of the German Society of Thorax, Heart and Vascular Surgery, 16-19 February, 2019, in Wiesbaden, Germany. This first health economic analysis concerning the study1, entitled „Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass – a case series,“ was conducted together with Prof. Dr. med. Karl Träger, Department of Cardiac Anesthesiology, University Hospital Ulm, Ulm, Germany.

The objectives of the analysis were to estimate the mean costs per patient of introducing CytoSorb as an adjuvant therapy compared to standard treatment without CytoSorb in the treatment of acute infective endocarditis from a German hospital perspective using intensive care unit (ICU) length of stay (LoS).

CytoSorb was used intraoperatively in patients with acute infective endocarditis (n=39). The control group was a historic cohort from the same hospital (n=28). Treated patients were overall sicker (median EuroScore II: 12.8 vs 10.2, p=0.03). Despite the low number of patients, the difference in the median ICU LoS of 2.5 days (7.5 vs. 5 days, p=0.059) suggests a reduction in the LoS.

A bootstrap analysis with 1,000 samples with 100 observations each (50:50) was performed based on the individual ICU LoS data of these patients from the university hospital. A probabilistic multivariable analysis performed by Monte Carlo simulations and a one-way sensitivity analysis to test for several cost driving variables were used to analyze the robustness of the result. Treatment with CytoSorb resulted in a median reduction in ICU LOS of 2.33 days (IQR: 1.5-3) of all treated patients according to the bootstrap analysis, a conservative estimate compared to the 2.5 days observed in the study.

The model estimated average savings of 1,660EUR per patient for the hospital with an 82% probability of being cost-saving even without any additional device-specific reimbursement. These savings rise to an average amount of 3,211EUR with a probability of 99% of being cost-saving when there is full reimbursement of the CytoSorb device costs (Fig. 1).

The costs of the ICU stay have the highest impact on the level of cost savings. However, CytoSorb remains cost saving irrespective of variations in all cost driving variables. The reduction in ICU LoS also opens the door to additional revenue for the hospital by being able to operate more patients since engaged ICU beds are often a bottleneck of a highly efficient cardiac surgery program.

Dr. Christian Steiner, Managing Director CytoSorbents Europe, said, „We strongly believe that the introduction of CytoSorb therapy has the potential to help many patients with different diseases. We are working very hard to build the necessary clinical data and evidence that it can be introduced in therapy guidelines soon.“

Prof. Dr.med. Karl Träger said, „We are using the CytoSorb therapy for several years now in different indications. The intraoperative application of CytoSorb for the treatment of acute infective endocarditis suggests a cost-saving impact, which is a great addition to the positive clinical effects we see.“

1Träger et al. IJAO. 2017; 40(5): 240-249

CytoSorb is a registered trademark of CytoSorbents Corporation.

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in new technologies and therapies in intelligent blood purification. CytoSorbents Europe GmbH is a hundred percent daughter company of CytoSorbents Corporation and coordinates the introduction and commercialization of CytoSorbents products worldwide.
Its flagship product, CytoSorb® is the first specifically-approved extracorporeal cytokine absorber in the European Union and it is distributed in more than 50 countries worldwide. CytoSorb was designed to reduce the „cytokine storm“ or „cytokine release syndrome,“ which is a major element of the deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. CytoSorbents“ purification technologies are based on biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. CytoSorb has been used in more than 56,000 human treatments to date.

CytoSorbents technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others.

For more information, please visit the Company“s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Company-Contact
CytoSorbents
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Press
Lucy Turpin Communications GmbH
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com